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In sensitivity analysis BIAsp remained dominant at half the study
HbA1c effect. CONCLUSIONS: For patients with uncontrolled
type 2 diabetes receiving current standard human insulin treat-
ment, the use of BIAsp represents a cost-effective treatment.
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OBJECTIVES: The Diabetes Decision Analysis of Cost—Type 2
(DiDACT) model is an established long-term model of disease
progression and health care resource utilisation for people with
Type 2 diabetes mellitus (T2DM). The objective of this project
was to adapt the DiDACT model to the Czech Republic health
care system taking the perspective of the payer, and to employ the
model to carry out comparative health economic evaluation of
Avandia (Rosiglitazone) in various therapeutic contexts. The
analyses focus on overweight and obese patients. METHODS:
The DiDACT economic model requires epidemiological, medical
resource use and medical cost data. These were updated to reﬂect
the Czech Republic setting where possible, such as for outpatient
costs, inpatient costs, cardio-vascular disease data and preva-
lence of complications at diagnosis. However, due to data avail-
ability constraints, some costs, resource use and epidemiology
data were drawn from previous analyses, undertaken in
Germany and the UK. The threshold for switching therapies was
7% HbA1c. In order to test the robustness of our results, uni-
variate sensitivity analyses were performed. RESULTS: The
resulting model allows assessment of the impact of new treat-
ment strategies or programmes in modifying risk factors for
diabetic complications and performing comparative cost-
effectiveness and cost-utility analysis. The model predicts that
adding Rosiglitazone to Metformin delays the onset of insulin
and produces better glycaemic control (HbA1c). The undis-
counted (discounted) lifetime incremental cost-effectiveness
ratios per QALY gained were 156,512 CZK (152,811 CZK) for
overweight patients, and 177,346 CZK (175,445 CZK) for obese
patients. CONCLUSIONS: The analyses yield incremental cost-
effectiveness ratios which fall below commonly accepted willing-
ness to pay thresholds. Rosiglitazone in combination with
Metformin is therefore a cost-effective option for the treatment
of T2DM when compared with conventional care of Metformin
in combination with sulphonylurea (SU) in overweight and obese
patients in the Czech Republic.
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OBJECTIVES: To compare the direct diabetes treatment costs
(DTC) in type 2 diabetes (T2D) patients treated with insulin
Glargine (GLA) to those with NPH insulin-based regimens
(NPH) in Germany. METHODS: A cost-minimization analysis
from the statutory health insurance (SHI) perspective was con-
ducted. Resource use data were collected within a cross-
sectional, retrospective study performed between February and
May 2007 in 199 primary care centres. Consecutive T2D
patients with SHI status treated with either GLA- or NPH-based
regimens for at least 6 months prior to study were enrolled. For
costing public price lists were used. DTC were calculated as
summarized costs of antidiabetic medications, blood glucose self-
monitoring (test strips, lancets), glucagon use and needles for a
6 months period. Sensitivity analyses for cost variables were
performed. RESULTS: A total of 1602 (982 GLA and 620 NPH)
patients were included. Mean DTC were €658  258 and
€685  242 per patient during 6 months in GLA and NPH
patients, respectively. NPH was mainly used in a basal-bolus
(ICT) (79%) whereas GLA was more frequently prescribed in a
basal-oral (BOT) antidiabetic regimen (43%). Higher basal
insulin costs for GLA vs. NPH (€194  97 vs. €116  74) during
6 months were compensated by lower costs for co-prescribed
short-acting insulins (€96  133 vs. €158  133). Further cost
compensations were due to a lower consumption of test strips
(375  249 vs. 447  251 units) and needles (159  142 vs.
185  176 units) per 6 month in GLA- vs. NPH-based regimens,
respectively. Hypoglycemia with consecutive glucagon use was
only reported for NPH (4 patients). Within the sensitivity analy-
ses the DTC for GLA remained lower vs. NPH. CONCLU-
SIONS: Under real-life conditions direct diabetes treatment costs
are similar in GLA and NPH treated T2D patients. As GLA is
advantageous for a patient due to reduced hypoglycemic risk, less
injection frequency and ﬂexible dosing compared to NPH, GLA
can be regarded as ﬁrst-line insulin approach in BOT and ICT.
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OBJECTIVES: To assess the health resource consumption and
the illness labour impact in diabetic patients and to study its
possible relation to patient’s glycemic control. METHODS: An
epidemiological, cross sectional, naturalistic study was carried
out in Spanish Primary Care centres. Patients >18 years with
diabetes mellitus type 1 (T1DM) or type 2, with insulin treatment
(T2DM-i) or not (T2DM-n.i), were enrolled in the study (con-
secutive cases sampling). The last value of glycosylated hemoglo-
bin (HbA1c) of each patient, reported in 2006, deﬁned the
glycemic control as satisfactory (HbA1c 7%) or unsatisfactory
(HbA1c > 7%). Health resource use due to illness monitoring,
acute and chronic complications and absenteeism days were col-
lected. RESULTS: A total of 679 patients were enrolled in the
study: 52.4% female; age 65.2 (13.7); BMI 28.81 (4.66); type of
diabetes: 11.5% T1DM, 26.2% T2DM-i and 62.3% T2DM-n.i;
mean time from diagnoses 11.9 (9.25) years. 53% of patients
achieved satisfactory control (T1DM: 29.5%, T2DM-i: 31.5%
and T2DM-n.i: 63.8%; p < 0.001). Mean number of annual
resource used related to Illness monitoring were: 11.4 primary
care medical visits, 8.9 nursing visits, 0.8 endocrine visits, 0.3
home visits, 4.4 blood analysis and 404.5 reactive strips. Acute
complications caused a mean annual use of 0.4 emergency visits
and 0.1 hospitalizations; and chronic complications 1.6 special-
ised visits (ophthalmology, nephrology and cardiology). Mean
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